, is a growing health problem in North America and worldwide. Little is known about the molecular alterations occurring in the tissue microenvironment during NTM pathogenesis. Utilizing next generation sequencing, we sequenced sputum and matched lymphocyte DNA in 15 MAC patients for a panel of 19 genes known to harbor cancer susceptibility associated mutations. Thirteen of 15 NTM subjects had a diagnosis of breast cancer (BCa) before or after NTM infection. Thirty three percent (4/12) of these NTM-BCa cases exhibited at least 3 somatic mutations in sputa compared to matched lymphocytes. Twenty four somatic mutations were detected with at least one mutation in ATM, ERBB2, BARD1, BRCA1, BRCA2, AR, TP53, PALB2, CASP8, BRIP1, NBN and TGFB1 genes. All four NTM-BCa patients harboring somatic mutations also exhibited 15 germ line BRCA1 and BRCA2 mutations. The two NTM subjects without BCa exhibited twenty somatic mutations spanning BRCA1, BRCA1, BARD1, BRIP1, CHEK2, ERBB2, TP53, ATM, PALB2, TGFB1 and 3 germ line mutations in BRCA1 and BRCA2 genes. A single copy loss of STK11 and AR gene was noted in NTM-BCa subjects. Periodic screening of sputa may aid to develop risk assessment biomarkers for neoplastic diseases in NTM patients.
The incidence and prevalence of nontuberculous mycobacterial lung disease (NTM) is increasing in USA and worldwide [1] [2] [3] [4] [5] [6] [7] [8] [9] . In the USA, a prevalence of 20 NTM cases out of 100,000 in 1997 and 47 cases out of 100,000 in 2007 was observed with an 8.2% annual increase 8 . NTM lung disease in the U.S.A. is primarily caused by Mycobacterium avium complex (MAC) and poses considerable challenges in diagnosis and treatment [1] [2] [3] [4] . NTM may occur in patients with or without a predisposing condition [1] [2] [3] [4] [5] [6] [7] [8] [9] . Postmenopausal women and individuals with various conditions such as bronchiectasis and cystic fibrosis are at risk of developing NTM disease [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] . Notably, the frequency of NTM patients with nodular bronchiectasis has increased over the past few years 8 . However, the underlying cellular and physiologic abnormalities causing NTM lung disease are not well understood 9 . In our recent study 8 , we observed that some women with stable NTM disease developed breast cancer (BCa) later in their lifetime, suggesting that NTM infection could be a potential risk factor for chronic inflammation and cellular transformation similar to Helicobacter pylori associated gastrointestinal transformation 11 . We rationalize that assessment of molecular abnormalities at infection sites and the surrounding environment would be important for continuous monitoring of the NTM infected patients. This will aid to develop suitable biomarkers for disease surveillance, treatment guidance and risk assessment.
Pattern of the somatic genomic variants in the sputum of NTM subjects with breast cancer. In this study, we have undertaken next generation sequencing (NGS) analysis of a 19-gene signature panel associated with cancer susceptibility and predisposition (Table 2) in women with NTM lung disease with (13) or without (two) a diagnosis of BCa. Matched lymphocytes and sputum DNA samples from thirteen NTM subjects with a history of BCa (NTM-BCa) and two subjects with NTM disease without BCa (NTM) were sequenced utilizing this high-throughput sequencing platform. Stringent data analysis and validation criteria were employed to determine both somatic and germ line mutations 35 . One subject did not pass quality control (NTM-BCa02) and was excluded from further analysis. Overall, we have detected numerous non-synonymous (Fig. 1A) and synonymous somatic mutations in these subjects (#PRJNA431897). Many unique somatic mutations were also identified in these samples (Fig. 1B) . Thirty three percent (4/12) of the NTM subjects with a previous history of breast cancer (NTM-BCa) exhibited at least 3 somatic mutations in the sputum when compared to the matched lymphocytes ( Table 2 , Fig. 1 ). A total of 24 somatic mutations were detected in the sputum samples of these subjects with at least one mutation in ATM, ERBB2, BARD1, BRCA1, BRCA2, TP53, PALB2, CASP8, BRIP1, NBN and TGFB1 gene. All the mutations were missense in nature (Table 3 , Figs 1 and 2 ). We detected a novel ERBB2 sequence variant (C-A, Ala > Glu; Table 3 ) in one NTM-BCa subject (NTM-BCa11), not reported previously. The genes most frequently harbored somatic mutations include ERBB2 (N = 5), BARD1 (N = 3), and BRCA2 (N = 3) (Fig. 2) . Notably, somatic mutations in BRCA1 and BRCA2 were detected in 75% (3/4) NTM-BCa subjects exhibiting mutations in the sputum (Table 3, Fig. 3 ). Pattern of somatic genomic variants in the sputum of women with NTM disease. Similar to the NTM patients with breast cancer history, both the NTM subjects (2/2, 100%) in the absence of breast cancer (Table 1 ) exhibited a number of somatic mutation in the sputum (Table 4 , Figs 1 and 2) . A total of 20 somatic mutations were detected in the sputum of these subjects with 11 mutations in one patient (NTM01) and 9 mutations in the other (NTM03) ( Table 4 ). The majority of the somatic mutation were spanning BRCA1 (N = 9) and BRCA2 (N = 2) and ERBB2 (N = 2) genes along with a single mutation in BARD1, BRIP1, CHEK2, TP53, ATM, PALB2 and TGFB1 molecules ( Table 4 , Figs 2 and 3) . Two ERBB2 gene mutations (chromosome position 37884037 and 37879588) that were detected in the NTM-BCa subjects (Table 3) were also present in the NTM subjects (Table 4) . Similar was the case for mutations in TP53 (chromosome position 7579472) and PALB2 (chromosome position 23646191) for the NTM-BCa and NTM subjects (Tables 3 and 4 ).
The spectrum of BRCA1 and BRCA2 germ line variants in the sputum of women with NTM-BCa. Germ line mutation in BRCA1 and BRAC2 genes are known risk factors for BCa development in women harboring mutation in these genes 25, 28, 32 . Other than somatic mutation, all the above described NTM-BCa patients (4/12, 33%) have exhibited a number of germline mutations in BRCA1 and BRCA2 genes ( Table 5 , Fig. 3 ). A total of 15 germ line BRCA1 (N = 8) and BRCA2 (N = 7) gene mutations were detected in these subjects (Table 4 , Fig. 3 ). All the mutations were missense in nature. Thus, both somatic as well as germ line mutations in BRCA1 and BRCA2 genes were evident in the NTM infected women with BCa (Tables 3 and 5 ; Fig. 3 ). Notably, subject NTM-BCa11, a past smoker (14 years) who harbored a novel ERBB2 variant (Table 3 ) and germ line BRCA2 mutation (Table 5) , had a family history of BCa, and was diagnosed with BCa and NTM at the same age (Table 1) . 
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Chr11 Distribution of BRCA1 and BRCA2 germ line variants in the sputum of NTM affected women. We also detected 3 germline mutation spanning BRCA1 and BRCA2 genes in both the NTM subjects (2/2, 100%) ( Table 5 , Fig. 3 ). Among the 3 germ line mutation, 2 were similar to that observed in the NTM patients with breast cancer history (chromosome position: 41245471, BRCA1; 32906729, BRCA2). However, the germ line mutation in BRCA1 (position: 41243840) was only detected in the NTM subject in the absence of BCa (Table 4) .
Copy number variation (CNV) in different genomic and chromosomal regions in the NTM affected women. The CNV analysis did not detect any breakpoints within genes for any samples (data not shown). No single sample contained more than one CNV in a target gene, although gains and losses in copy number periodically occurred throughout the rest of the genome. Lowering the CNV log2 call threshold to 0.2 (the default option in CNVkit) resulted in additional gains and losses of some chromosomal segments (data not shown), but only the high-confidence calls from a more stringent log2 threshold of 0.3 were presented. A single copy loss of a lung and breast cancer risk associated gene STK11 (a.k.a. LKB1) was noted in 25% (3/12) of the NTM subjects with breast cancer history (Fig. 4A) . A single copy loss of the Androgen Receptor gene (AR) was also noted in one NTM subject with BCa history (Fig. 4B) . A single copy loss in chromosome 5 and 16 was noted in BCa-NTM10 (Fig. 4C ) and copy number loss in chromosome 17 was noted in subject BCa-NTM11 (Fig. 4D ) who had a history of breast cancer and smoking as described above. These CNVs observed in chromosome 5, 16 and 17 were not associated with the 19 gene panels we have analyzed (Fig. 4C ).
Discussion
Pulmonary NTM disease (especially disease due to MAC) is a rising health concern in USA and throughout the world 8 . Many of these NTM patients develop therapeutic resistance posing significant challenges to disease management 1, 9 . Infection with MAC particularly in the treatment resistant patients may lead to molecular changes associated with inflammation and tumorigenesis in surrounding epithelial tissues niche. In a recent study, infection of normal human lung airway epithelial cells with MAC triggered enhanced expression of CCL20, IL-32 and CXCL8 proteins 36 . These proteins are known to promote BCa growth, invasion and progression to metastasis [37] [38] [39] [40] [41] [42] [43] . These molecules were also demonstrated to promote lung cancer 40, [43] [44] [45] [46] [47] . A recent study also uncovered functional involvement of intratumoral pathogenic bacteria in facilitating chemotherapeutic resistance in colon cancer patients 48 . Thus, NTM infected patients may remain at risk of developing neoplastic disease in their life time. Investigation of the molecular genetic alterations in the surrounding tissue microenvironment of the infected sites is important and could aid in developing disease monitoring and risk assessment strategies.
Next generation sequencing platform has revolutionized characterization of molecular genetic abnormalities resulting from infection or genotoxic damages in various affected cell types [49] [50] [51] [52] . Free circulating DNA released from the infected or malignant cells often serves as monitoring/surveillance biomarkers and can also offer better therapeutic guidance [53] [54] [55] . Increased sputum production is one of the major symptoms due to NTM lung infection and sputum could be a valuable resource to identify free DNA not only associated with NTM pathogenesis but also inflammatory changes resulted from infection. Free circulating DNA associated with altered methylation, inflammation and cancer has been detected in sputum of COPD and lung cancer patients [56] [57] [58] [59] [60] . We identified cancer associated predisposing genetic mutations in sputum of women with NTM lung infection with or without a diagnosis of BCa. This novel finding confirms the presence of mutated DNA in sputum samples of NTM infected patients. Numerous genes exhibiting somatic mutations in these subjects such as EBBB2, PALB2, TP53, ATM, STK11 and TGFB1 are involved in various malignancies including BCa 16, 18, 23, 61 . The majority of the women in our study cohort had been diagnosed with BCa before or after the diagnosis of NTM disease. Patient 11 (NTM-BCa11), a former smoker with a high BMI and family history of breast cancer was simultaneously diagnosed with NTM and early stage BCa (stage 0) at age 68. This patient was detected with a novel somatic ERBB2 mutation and germ line BRCA2 mutation accompanied by copy number loss in chr.17. Similarly, patient 12 (NTM-BCa-12) with a history of alcohol consumption who was diagnosed with NTM (MAC) at age 55 and stage-IB breast cancer at age 61 exhibited numerous somatic and germ line BRCA1 and BRCA2 mutations in the sputum. The two NTM subjects with low BMI and exhibiting somatic/germ line BRCA1 and BRCA2 mutations had presented with abnormal mammograms during their routine examination. Except for subject NTM01, they 
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Chr17 Table 5 . Distribution of germline mutations in BRCA1 and BRCA2 in women both NTM-BCa and NTM disease. also had a history of alcohol consumption and tobacco smoking. Collectively, these findings suggest an association between NTM (MAC) lung disease and BCa development in these women and warrants breast examinations and routine screening of sputum for predisposing mutation detection. STK11 (a.k.a. LKB1) is a critical regulator of mammary tumorigenesis [62] [63] [64] . Functional inactivation or loss of STK11 was shown to promote breast cancer initiation and progression to metastasis [62] [63] [64] . A functional coordination between STK11 with ERBB2 in mediating these effects in mammary tumorigenesis was also demonstrated [62] [63] [64] . The STK11 is also one of the most frequently inactivated genes in non-small cell lung cancer 65 . Loss of STK11 copy in multiple NTM-BCa subjects also suggests association with malignant transformation in these women. Notably, one of these women with STK11 alteration (NTM-BCa04) was diagnosed with NTM disease at age 57 and stage-I breast cancer at 61. These findings further suggest a functional correlation between NTM and malignant disease development in these women. Androgen receptor (AR) expression predicts better prognosis and survival of breast cancer patients 34 and reduced AR expression promotes initiation of ERBB2 induced mammary tumorigenesis 66 . Thus, the loss of AR copy number observed in one NTM-BCa subject could also be associated with neoplastic transformation in this subject.
Germ line pathogenic variants in BRCA1 and BRCA2 are predisposing genetic factors associated with enhanced risk of BCa in the lifetime of an individual as demonstrated in numerous studies 12, 25, 26, 28, [31] [32] [33] . In this study, 40% of NTM affected women irrespective of their BCa diagnosis status exhibited germ line BRCA1 and BRCA2 mutations. Thus, NTM patients with long term infections and predisposing cancer associated genetic mutations may be at risk of developing malignant diseases in their life-time. Comparing the number of somatic mutations between the NTM-BCa (4/13) and the NTM (2/2) groups, there was no statistically significant relationship between breast cancer status and somatic mutation (p = 0.06) among NTM patients. Similarly, no statistically significant relationship was established for NTM-BCa with germ line (p = 0.06) mutation and copy number variations (p = 0.214).
To our knowledge, this is the first study, which revealed cancer associated gene mutations (both somatic and germ line) in sputum of NTM (MAC) infected subjects with or without a diagnosis of breast cancer. These findings suggest that chronic infection with NTM may trigger inflammation and cellular transformation surrounding the infection sites (immune and epithelial cells). Therefore, these subjects may potentially be at risk of acquiring transformational changes due to chronic NTM infection. Earlier, we have detected oncogenic ECM1 protein in the circulating exosomes of these subjects 8 . These findings collectively suggest for an increased risk of the NTM affected subjects towards oncogenic transformation. Helicobacter pylori infection is a relevant example facilitating gastrointestinal tumorigenesis 11 . This study suggests a novel avenue for study and may warrants monitoring of these subjects not only for NTM progression but also cellular transformation. In the clinical setting, molecular assessment of sputa by high throughput sequencing of NTM affected subjects may identify novel genetic alterations. A consensus panel of such molecular alterations could serve as biomarker for monitoring the risk of developing neoplastic disease in these patients as do BRCA1, BRCA2 and ER/PR/HER2 biomarkers for BCa [25] [26] [27] 52 . 
Methods
Human samples and ethical statement. Matched normal lymphocytes and sputa with relevant clinical information such as age, grade, stage, diagnosis etc. were collected from 13 NTM-BCa and 2 NTM subjects (de-identified, Table 1 ). The Institutional Review Board of The University of Texas Health Science Center at Tyler approved this study (#974). All subjects had sputum cultures which were culture positive for MAC infection by acid fast bacilli (AFB) sputum analysis 8 . Informed consent was obtained from all the patients. All methods were performed in accordance with the relevant guidelines and regulations.
Sputum collection and quality control. Routine expectorated sputa were collected and cultured as necessary for detection of AFB [67] [68] [69] . Samples were processed using standard decontamination procedures, fluorochrome microscopy and cultured on solid and liquid media as recommended by the Clinical and Laboratory Standards Insititute (CLSI) guidelines for mycobacteria detection and culture 67, 69 . MAC isolates were identified using AccuProbe (Hologic Gen-Probe Inc) 68 . For decontamination, the N-acetyl-L-cysteine-sodium hydroxide method alone or in combination with oxalic acid was used 70 . All methods were performed in accordance with relevant guidelines and regulations.
DNA extraction and quantification. The lymphocytes were isolated from whole blood as described 71 . Genomic DNA was extracted from lymphocytes and sputa by digesting samples with 1% sodium dodecyl sulfate/ proteinase K mixture overnight at 55 °C. The DNA was then extracted by phenol-chloroform, and ethanol precipitation and suspended in Tris-EDTA buffer and concentration was measured using the Nanodrop System. For sequencing analysis, 1 µg of DNA was used.
Next generation sequencing of the predisposing human gene panel. Utilizing next generation sequencing (NGS) platform 35 , we sequenced sputum and matched lymphocyte DNA of 15 NTM subjects for a panel 19 genes known to harbor mutations associated with cancer susceptibility and neoplastic transformation ( Table 2) 12-34 . A total of 313 exons (coding regions) covering 63619 base pair regions of these 19 genes were mapped. We utilized a custom oligonucleotide-based capture with sequencing of regions within these 19 genes on Illumina HiSeq platform.
Data analysis and validation. The analysis pipeline utilizes genome analysis tool kit (GATK) standards, includes quality assessment with FASTQC 72 followed by mapping reads to human reference genome GRCh37. p13 (hg19). SNVs and indels with depth of coverage >10 were called using Burrows-Wheeler Aligner (BWA) 73 and Sequence Alignment/Map (SAM) tools 74 , with annotation from the Human Genetic Mutation Database using SnpEff 75 . When multiple annotations for gene location were available, the most severe was reported (e.g., missense variant scored instead of non-coding exon variant). Following Winter et al. 32 , variants were classified as somatic if they were present only in the sputa; and germ line if they were present in both the lymphocyte and sputa compared to the reference sequence. Variants present only in the lymphocytes were excluded from subsequent analysis. Sequence data have been submitted to the NCBI Sequence Read Archive and can be found under accession (BioProject #PRJNA431897). Scripts used for filtering and visualizing results can be found at https:// github.com/k8hertweck/breastCancerNTM.
Copy number variation analysis. CNVs were assessed using CNVkit 76 . This software uses both target (e.g., from cancer associated genes) and off-target reads to call copy number across the genome, and is most accurate in detecting CNVs larger than 1 mega base pair (Mbp) spanning multiple exons (or captured regions). Log2 values for segment calls were summarized for visualization purposes. Given the uncertainty in assessing levels of copy number heterogeneity associated with these samples, the log2 threshold of 0.3 (as recommended by the CNV kit manual) was applied to call gains or losses in copy number of target genes.
Statistical analysis.
We employed Binomial test for proportion to compare mutation outcome among various groups.
